KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$4.3 million.

  • Esperion Therapeutics' Cash from Operations rose 8786.69% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$93.3 million, marking a year-over-year decrease of 26217.1%. This contributed to the annual value of -$23.7 million for FY2024, which is 8254.15% up from last year.
  • Per Esperion Therapeutics' latest filing, its Cash from Operations stood at -$4.3 million for Q3 2025, which was up 8786.69% from -$31.4 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Cash from Operations high stood at $53.8 million for Q1 2024, and its period low was -$89.1 million during Q1 2021.
  • For the 5-year period, Esperion Therapeutics' Cash from Operations averaged around -$34.5 million, with its median value being -$37.1 million (2023).
  • As far as peak fluctuations go, Esperion Therapeutics' Cash from Operations skyrocketed by 19902.86% in 2024, and later plummeted by 33611.38% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Cash from Operations (Quarter) stood at -$57.7 million in 2021, then increased by 26.4% to -$42.5 million in 2022, then grew by 12.75% to -$37.1 million in 2023, then grew by 5.68% to -$35.0 million in 2024, then surged by 87.74% to -$4.3 million in 2025.
  • Its Cash from Operations was -$4.3 million in Q3 2025, compared to -$31.4 million in Q2 2025 and -$22.6 million in Q1 2025.